Alyeska Investment Group
SYRE icon

Alyeska Investment Group’s Spyre Therapeutics SYRE Stock Holding History

Alyeska Investment Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,677
Closed -$576K – 523
2017
Q3 		$576K Buy
4,677
+84
+2% +$7.87K ﹤0.01% 438
2017
Q2 		$442K Sell
4,593
-140
-3% -$19.4K ﹤0.01% 434
2017
Q1 		$881K Sell
4,733
-55
-1% -$7.76K 0.01% 439
2016
Q4 		$521K Buy
4,788
+402
+9% +$58.6K ﹤0.01% 445
2016
Q3 		$703K Buy
4,386
+386
+10% +$53.7K 0.01% 424
2016
Q2 		$486K Buy
+4,000
New +$767K ﹤0.01% 404

Other funds holding SYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Alyeska Investment Group's SYRE Position: Q4 2017 in Review

Alyeska Investment Group sold out of Spyre Therapeutics (SYRE) in Q4 2017, closing a stake of 4,677 shares — an estimated $576K sold.

Alyeska Investment Group first reported a position in SYRE in Q2 2016 and held it in 6 quarters. The position peaked at $881K in Q1 2017. 31 funds tracked by Wall St. Rank hold SYRE as of Q4 2017.

  • Alyeska Investment Group reported no remaining Spyre Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Alyeska Investment Group sold 4,677 Spyre Therapeutics shares in Q4 2017, an estimated $576K.
  • Alyeska Investment Group first reported a position in Spyre Therapeutics in Q2 2016 and held it in 6 quarters.
  • Alyeska Investment Group's Spyre Therapeutics position peaked at $881K in Q1 2017.
  • 31 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2017.

Based on Alyeska Investment Group's 13F filing for Q4 2017, filed 14 Feb 2018.